Company Description
International Flavors & Fragrances Inc., together with its subsidiaries, manufactures and markets food, beverage, health and biosciences, scent, pharma solutions, and complementary adjacent products in the United States, Europe, and internationally.
It operates in four segments Nourish, Health & Biosciences, Scent, and Pharma Solutions. The Nourish segment consists of portfolio of natural-based ingredients that includes plant-based specialty food ingredients, such as soy and pea protein with value-added formulations, emulsifiers, and sweeteners; food protection ingredients, including natural antioxidants, and anti-microbials for natural food preservation and shelf-life extension; savory solutions, such as spices, marinades, and mixtures; combining flavourings with fruits, vegetables, and other natural ingredients products; a range of flavor compounds used in savory products, such as soups, sauces, meat, fish, poultry, and snacks; and beverages juice drinks, carbonated or flavored beverages, and spirits, as well as sweets bakery products, candy, cereal, and chewing gum; and dairy products, such as yogurt, ice cream, and cheese, as well as spices and seasoning ingredients.
Its Health & Biosciences is comprised of health, cultures and food enzymes, home and personal care, animal nutrition, and grain processing.
The Scent segment creates fragrance compounds, and fragrance ingredients. Its Pharma Solutions segment produces cellulosics and seaweed-based pharmaceutical excipients.
The company was incorporated in 1909 and is headquartered in New York, New York.
| Country | United States |
| Founded | 1833 |
| Industry | Specialty Chemicals |
| Sector | Materials |
| Employees | 22,400 |
| CEO | Jon Erik Fyrwald |
Contact Details
Address: 521 West 57th Street New York, New York 10019-2960 United States | |
| Phone | 212 765 5500 |
| Website | iff.com |
Stock Details
| Ticker Symbol | IFF |
| Exchange | NYSE |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000051253 |
| CUSIP Number | 459506101 |
| ISIN Number | US4595061015 |
| Employer ID | 13-1432060 |
| SIC Code | 2860 |
Key Executives
| Name | Position |
|---|---|
| Jon Erik Fyrwald | Chief Executive Officer and Director |
| Dr. Jennifer Amy Johnson Ph.D. | Executive Vice President, General Counsel and Corporate Secretary |
| Simon Herriott | President of Health and Biosciences |
| Yuvraj Arora | President of Taste Division and Chief Commercial Officer |
| Michael DeVeau | Executive Vice President and Chief Financial Officer |
| Ralf Finzel Ph.D. | Executive Vice President and Global Operations Officer |
| Beril Yildiz | Senior Vice President, Corporate Controller and Chief Accounting Officer |
| Vivek Verma | Executive Vice President and Chief Information Officer |
| Deborah Borg | Executive Vice President and Chief People and Culture Officer |
| Dr. Angela Strzelecki | President of Pharma Solutions |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 18, 2025 | ARS | Filing |
| Mar 18, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Mar 18, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 13, 2025 | 8-K | Current Report |
| Feb 28, 2025 | 10-K | Annual Report |
| Feb 20, 2025 | 8-K | Current Report |
| Feb 18, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 13, 2025 | SCHEDULE 13G/A | Filing |
| Dec 19, 2024 | 8-K | Current Report |